Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The goal of this clinical trial is to learn whether a digital lifestyle app can help improve diet, physical activity, symptoms, emotional well-being, and quality of life in adults with myeloproliferative neoplasms (MPNs).
The main questions it aims to answer are:
Can people with MPNs use the WELL-MPN app?
Does using the WELL-MPN app improve diet quality and physical activity?
Does the WELL-MPN app improve MPN-related symptoms, anxiety and depression, confidence in managing health, and overall quality of life?
Researchers will compare participants who use the WELL-MPN digital app with participants who receive written educational materials about diet and physical activity for people with cancer to see if the app leads to greater improvements in lifestyle behaviors, symptoms, and well-being.
Participants will:
Be randomly assigned to use the WELL-MPN app or receive written lifestyle education materials
Use the assigned program or materials over the study period
Complete surveys about diet, physical activity, symptoms, mood, confidence in self-care, and quality of life
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| WELL-MPN Digital App | Experimental | WELL-MPN app and usual care |
|
| Enhanced Usual Care | No Intervention | Usual care and written literature about diet and physical activity guidelines in patients with cancer |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| WELL-MPN Digital App | Behavioral | Patients randomized to the WELL-MPN arm will be given access to the WELL-MPN digital program (app) which provides lifestyle counseling through an iPad. |
| Measure | Description | Time Frame |
|---|---|---|
| Number of patients consented and enrolled onto the study, and number of patients who complete at least 2 out of 3 modules in the app. | Primary outcome is feasibility, defined as ≥60% enrollment of eligible patients and ≥70% of patients randomized to the intervention group completing at least 2 out of 3 of app modules. | 2 years |
| 8-Item Client Satisfaction Scores (CSQ-8) | Acceptability of WELL-MPN as measured by CSQ-8 scores of WELL-MPN. The CSQ-8 is a self-report tool designed to measure patient satisfaction with a received intervention. It consists of 8 items rated on a 4-point Likert scale (from "quite dissatisfied" to "very satisfied"), with higher scores indicating greater satisfaction. WELL-MPN is considered acceptable if >80% of participants on the WELL-MPN arm report a CSQ-8 score >20. | Enrollment to 16 weeks after enrollment |
| Measure | Description | Time Frame |
|---|---|---|
| Healthy Eating Index calculated from the Automated Self-Administered Dietary Assessment Tool | Diet quality will be compared between control and WELL-MPN patients. The ASA24 is a free 24-hour dietary recall tool developed by the National Cancer Institute. Responses will be used to calculate a Healthy Eating Index (HEI) score, which is a measure of dietary quality that addresses compliance with the 2015 United States Department of Agriculture dietary guidelines (scores range from 0 to 100, with higher scores indicating greater alignment with dietary guidelines). |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Chi-Joan How | Contact | 617-732-5190 | jhow@bwh.harvard.edu |
| Name | Affiliation | Role |
|---|---|---|
| Chi-Joan How | Massachusetts General Hospital | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Mass General Brigham | Boston | Massachusetts | 02115 | United States |
Not provided
| ID | Term |
|---|---|
| D009196 | Myeloproliferative Disorders |
| D013920 | Thrombocythemia, Essential |
| D011087 | Polycythemia Vera |
| D055728 | Primary Myelofibrosis |
| ID | Term |
|---|---|
| D001855 | Bone Marrow Diseases |
| D006402 | Hematologic Diseases |
| D006425 | Hemic and Lymphatic Diseases |
| D001778 | Blood Coagulation Disorders |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Enrollment to 16 weeks after enrollment. |
| Mini Eating Assessment Tool (Mini-EAT) score | Diet quality will be compared between control and WELL-MPN patients. The Mini-EAT is a 9-item validated brief dietary screener designed for greater ease of administration compared to the ASA-24 but has strong correlation with the HEI. Responses generate a score ranging from 0 to 54, with higher scores reflecting greater adherence to healthy dietary patterns aligned with the Dietary Guidelines for Americans. | Enrollment to 16 weeks after enrollment. |
| Godin Leisure Time Exercise Questionnaire | Physical activity will be compared between control and WELL-MPN patients. The Godin Leisure Time Exercise Questionnaire is a brief, self-reported tool used to assess a person's usual physical activity during their free time.It consists of three questions asking information on the number of times one engages in mild, moderate, and strenuous physical activity of at least 15-minute durations in a typical week. Higher scores indicate greater physical activity, with scores of less than 14 units indicating insufficient / sedentary activity. | Enrollment to 16 weeks after enrollment. |
| Patient-Reported Outcomes Measurement Information System (PROMIS) Self-Efficacy Short Forms | Self-efficacy will be compared between control and WELL-MPN patients. The PROMIS Self-Efficacy Short Forms include 4-item scales across domains such as managing daily activities, symptoms, medications, emotions, and social interactions. Each item is rated on a 5-point Likert scale, with higher scores indicating greater self-efficacy. | Enrollment to 16 weeks after enrollment. |
| MPN Symptom Assessment Form (SAF) Total Symptom Score (TSS) | MPN symptom scores will be compared between control and WELL-MPN patients. The MPN SAF TSS is a 10-item questionnaire assessing the most representative and clinically relevant MPN symptoms (concentration, early satiety, inactivity, night sweats, itching, bone pain, abdominal discomfort, weight loss, fever), and includes a "worst fatigue" question from the Brief Fatigue Inventory. Each subscale ranges from 0 (absent / as good as it can be) to 10 (worst imaginable / as bad as it can be), and scores are computed as the average of the observed items multiplied by 10 to achieve a 0 to 100 scale. | Enrollment to 16 weeks after enrollment. |
| Hospital Anxiety and Depression Scale (HADS-A and HADS-D): | Psychological distress will be compared between controls and WELL-MPN patients. The 14-item HADS consists of two 7-item subscales assessing anxiety and depression symptoms in the past week. Each subscale ranges from 0 (no distress) to 21 (maximum distress), with higher scores indicating worse distress. Subscale scores > 8 indicate clinically significant distress; scores can be further interpreted as follows: 8-10 indicates mild distress, 11-14 indicates moderate distress, and 15-21 indicates severe distress. | Enrollment to 16 weeks after enrollment. |
| Functional Assessment of Cancer - General (FACT-G) | Quality of life will be compared between controls and WELL-MPN patients. The FACT-G consists of four subscales assessing well-being across four domains (physical, functional, emotional, and social). Subscale scores include Functional Well-Being (0-28), Social Well-Being (0-28), Emotional Well-Being (0-24), and Functional Well-Being (0-28) with higher scores reflecting better well-being in each domain. | Enrollment to 16 weeks after enrollment. |
| D013922 | Thrombocytosis |
| D001791 | Blood Platelet Disorders |
| D006474 | Hemorrhagic Disorders |
| D019046 | Bone Marrow Neoplasms |
| D019337 | Hematologic Neoplasms |
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |